{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Lyka Labs Ltd
Lyka Labs Stock Falls to 52-Week Low of Rs.77.32 Amidst Continued Downtrend
Lyka Labs has reached a new 52-week low of Rs.77.32 today, marking a significant decline amid a sustained downward trend over recent sessions. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology space.
Lyka Labs Sees Revision in Market Assessment Amidst Challenging Financial Trends
Lyka Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting ongoing challenges in its financial and technical outlook. The recent changes in evaluation metrics highlight concerns across several key parameters, signalling a cautious stance from market analysts.
Lyka Labs Stock Falls to 52-Week Low of Rs.78.01 Amidst Continued Downtrend
Lyka Labs has reached a new 52-week low of Rs.78.01 today, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges.
Lyka Labs Stock Falls to 52-Week Low of Rs.78.88 Amidst Continued Downtrend
Lyka Labs has reached a new 52-week low of Rs.78.88 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past six consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.
Lyka Labs Stock Falls to 52-Week Low of Rs.82.9 Amidst Weak Financials
Lyka Labs, a company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low price of Rs.82.9 as of today, marking a significant decline in its stock performance over the past year. This development comes amid a backdrop of subdued financial results and valuation metrics that reflect ongoing challenges within the company.
Why is Lyka Labs falling/rising?
As of 18-Nov, Lyka Labs Ltd's stock price is Rs. 82.93, down 3.06%, marking a new 52-week low and a total decline of 9.9% over the past four days. The stock is underperforming significantly compared to the Sensex, with year-to-date returns down 47.73% against the benchmark's gain of 8.36%.
Lyka Labs Falls to 52-Week Low of Rs.85 Amidst Continued Downtrend
Lyka Labs has reached a new 52-week low of Rs.85, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market factors that have influenced investor sentiment.
Lyka Labs Hits 52-Week Low at Rs. 85.55 Amid Market Gains
Lyka Labs has reached a new 52-week low, reflecting a challenging performance with a year-to-date decline of 39.31%. The stock has underperformed its sector and is trading below key moving averages. Financial metrics indicate significant issues, including a high debt-to-equity ratio and a notable drop in profitability and net sales.
Is Lyka Labs overvalued or undervalued?
As of November 13, 2025, Lyka Labs is considered overvalued with a high PE ratio of 156.53 and a significant decline in performance, contrasting with its peers, which have more attractive valuations and growth expectations.
Why is Lyka Labs falling/rising?
As of 13-Nov, Lyka Labs Ltd's stock price is Rs. 89.47, down 2.79%, and has reached a 52-week low of Rs. 86.76. The stock has underperformed its sector and the broader market, with significant negative returns over the past week, month, and year, despite increased investor participation.
Are Lyka Labs latest results good or bad?
Lyka Labs' latest results are concerning, showing a 10.93% decline in net sales year-on-year, negative operating profit, and a net loss of ₹3.36 crores, indicating significant operational challenges and compromised efficiency. Investors should monitor future quarters for potential recovery.
Lyka Labs Faces Significant Financial Challenges Amid Declining Sales and Profitability
Lyka Labs, a microcap in the Pharmaceuticals and Biotechnology sector, reported a challenging quarter ending September 2025, with a profit after tax of Rs -3.36 crore and net sales of Rs 36.66 crore, down nearly 11%. The company's earnings per share and operating profit metrics also showed significant declines.
Lyka Labs Hits New 52-Week Low at Rs. 90 Amid Market Struggles
Lyka Labs has hit a new 52-week low, reflecting a significant decline in stock performance and underperformance compared to its sector. Over the past year, the company has faced a substantial drop in profitability and sales, despite maintaining high management efficiency and long-term growth potential. Concerns persist due to a high debt-to-equity ratio.
Lyka Labs Q2 FY26: Sharp Losses Amid Operational Collapse
Lyka Labs Ltd. reported a consolidated net loss of ₹3.36 crores in Q2 FY26, a dramatic reversal from the ₹0.93 crores profit posted in the previous quarter, marking a sequential deterioration of 461.29%. Year-on-year, the loss widened by 260.00% compared to the ₹2.10 crores profit in Q2 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹326.85 crores, saw its stock trading at ₹91.58 on November 13, down 0.50% from the previous close and hovering near its 52-week low of ₹90.00.
How has been the historical performance of Lyka Labs?
Lyka Labs has shown fluctuating historical performance, with net sales increasing from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, while total operating income peaked at 194.08 Cr in Mar'22 before declining. Despite rising costs and low cash flow, the company improved profitability, achieving a profit after tax of 7.93 Cr in Mar'25, recovering from previous losses.
Why is Lyka Labs falling/rising?
As of 20-Oct, Lyka Labs Ltd's stock price is Rs 93.82, down 0.61%, and has fallen for three consecutive days, totaling a 1.72% decline. The stock is underperforming significantly compared to the Sensex, with a year-to-date drop of 40.86% amidst a generally positive market.
Lyka Labs Hits 52-Week Low, Trading at Rs 90.2
Lyka Labs has reached a 52-week low, reflecting a significant decline in value over the past year, contrasting with the broader market's performance. The company faces challenges with a high debt-to-equity ratio but demonstrates strong management efficiency and consistent operating profit growth. The Nifty index shows positive momentum across market segments.
Lyka Labs Hits New 52-Week Low at Rs 115.00 Amid Market Struggles
Lyka Labs has reached a 52-week low amid a broader decline in the Pharmaceuticals & Drugs sector. Despite recent challenges, including a significant drop in stock performance, the company has shown strong management efficiency and consistent operating profit growth over the past year, highlighting its operational resilience.
Lyka Labs Hits New 52-Week Low, Trading at Rs 95.3
Lyka Labs has reached a 52-week low, reflecting significant challenges in its stock performance, with a notable decline over the past year. The company faces high debt levels but has shown strong management efficiency and consistent positive results, indicating potential for long-term growth despite current difficulties.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
